Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors

[1]  James D. Griffin,et al.  Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia , 2007, Nature Reviews Cancer.

[2]  Helge Weissig,et al.  Functional interrogation of the kinome using nucleotide acyl phosphates. , 2007, Biochemistry.

[3]  G. Superti-Furga,et al.  Dasatinib (BMS354825) Inhibits IgE-Dependent Activation and Histamine Release in Human Blood Basophils. , 2006 .

[4]  Ping Chen,et al.  2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase in , 2006, Journal of medicinal chemistry.

[5]  W. Vogel,et al.  Discoidin domain receptor 1-deficient mice are resistant to bleomycin-induced lung fibrosis. , 2006, American journal of respiratory and critical care medicine.

[6]  C. Ford,et al.  Sensing extracellular matrix: an update on discoidin domain receptor function. , 2006, Cellular signalling.

[7]  F. Lee,et al.  Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. , 2006, Blood.

[8]  N. Gray,et al.  Rational design of inhibitors that bind to inactive kinase conformations , 2006, Nature chemical biology.

[9]  C·霍普夫,et al.  Process for the identification of novel enzyme interacting compounds , 2006 .

[10]  S. Hall,et al.  Chemoproteomics-driven drug discovery: addressing high attrition rates. , 2006, Drug discovery today.

[11]  T. Haystead.  The purinome, a complex mix of drug and toxicity targets. , 2006, Current topics in medicinal chemistry.

[12]  C. Niemeyer,et al.  Effect of STI-571 (imatinib mesylate) in combination with retinoic acid and gamma-irradiation on viability of neuroblastoma cells. , 2006, Biochemical and biophysical research communications.

[13]  G. Ferry,et al.  NRH:quinone reductase 2: an enzyme of surprises and mysteries. , 2005, Biochemical pharmacology.

[14]  A. Fliri,et al.  Analysis of drug-induced effect patterns to link structure and side effects of medicines , 2005, Nature chemical biology.

[15]  D. Campbell,et al.  Phosphodiesterase 3A binds to 14-3-3 proteins in response to PMA-induced phosphorylation of Ser428. , 2005, The Biochemical journal.

[16]  William Pao,et al.  Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Kevan M Shokat,et al.  Features of selective kinase inhibitors. , 2005, Chemistry & biology.

[18]  L. Wodicka,et al.  A small molecule–kinase interaction map for clinical kinase inhibitors , 2005, Nature Biotechnology.

[19]  I. Graef,et al.  Recruitment of the Extracellular Signal-Regulated Kinase/Ribosomal S6 Kinase Signaling Pathway to the NFATc4 Transcription Activation Complex , 2005, Molecular and Cellular Biology.

[20]  Ping Chen,et al.  Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. , 2004, Journal of medicinal chemistry.

[21]  A. Ullrich,et al.  Strategies to overcome resistance to targeted protein kinase inhibitors , 2004, Nature Reviews Drug Discovery.

[22]  M. Cotten,et al.  Chemical Proteomic Analysis Reveals Alternative Modes of Action for Pyrido[2,3-d]pyrimidine Kinase Inhibitors* , 2004, Molecular & Cellular Proteomics.

[23]  K. Parker,et al.  Multiplexed Protein Quantitation in Saccharomyces cerevisiae Using Amine-reactive Isobaric Tagging Reagents*S , 2004, Molecular & Cellular Proteomics.

[24]  C. Daniels,et al.  Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. , 2004, The Journal of clinical investigation.

[25]  Min Wu,et al.  Fishing for targets: novel approaches using small molecule baits. , 2004, Drug discovery today. Technologies.

[26]  D. Fabbro,et al.  Structural insights into the conformational selectivity of STI-571 and related kinase inhibitors. , 2004, Current opinion in drug discovery & development.

[27]  Richard Morphy,et al.  From magic bullets to designed multiple ligands. , 2004, Drug discovery today.

[28]  C. Heldin,et al.  Suppressors of T-cell Receptor Signaling Sts-1 and Sts-2 Bind to Cbl and Inhibit Endocytosis of Receptor Tyrosine Kinases* , 2004, Journal of Biological Chemistry.

[29]  Fei Ye,et al.  7-Alkoxy-4-phenylamino-3-quinolinecar-bonitriles as dual inhibitors of Src and Abl kinases. , 2004, Journal of medicinal chemistry.

[30]  Oliver Hantschel,et al.  Regulation of the c-Abl and Bcr–Abl tyrosine kinases , 2004, Nature Reviews Molecular Cell Biology.

[31]  M. Cotten,et al.  An efficient proteomics method to identify the cellular targets of protein kinase inhibitors , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Peter G. Schultz,et al.  Synthetic small molecules that control stem cell fate , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Li Fang,et al.  p53 induction and activation of DDR1 kinase counteract p53‐mediated apoptosis and influence p53 regulation through a positive feedback loop , 2003, The EMBO journal.

[34]  D. Boschelli,et al.  SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. , 2003, Cancer research.

[35]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[36]  Timothy A J Haystead,et al.  Discovery of novel targets of quinoline drugs in the human purine binding proteome. , 2002, Molecular pharmacology.

[37]  Doriano Fabbro,et al.  Targeting protein kinases in cancer therapy. , 2002, Current opinion in drug discovery & development.

[38]  M. Mann,et al.  Large-scale Proteomic Analysis of the Human Spliceosome References , 2006 .

[39]  Alex Matter,et al.  Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug , 2002, Nature Reviews Drug Discovery.

[40]  P. Cohen.  Protein kinases — the major drug targets of the twenty-first century? , 2002, Nature reviews. Drug discovery.

[41]  A. Orth,et al.  Large-scale analysis of the human and mouse transcriptomes , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[42]  T. Ganesan,et al.  Functional analysis of discoidin domain receptor 1: effect of adhesion on DDR1 phosphorylation , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[43]  T. Jacks,et al.  STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications , 2001, Oncogene.

[44]  T. C. Jenkins,et al.  Bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by human NAD(P)H quinone oxidoreductase 2: a novel co-substrate-mediated antitumor prodrug therapy. , 2000, Cancer research.

[45]  J Mottram,et al.  Intracellular targets of cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised inhibitors. , 2000, Chemistry & biology.

[46]  Jürg Zimmermann,et al.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.

[47]  A. Shevchenko,et al.  Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. , 1996, Analytical chemistry.

[48]  T. Meyer,et al.  Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. , 1996, Cancer research.

[49]  C. Lowe,et al.  Some parameters relevant to affinity chromatography on immobilized nucleotides. , 1973, The Biochemical journal.